Theme: Exploring the Possibilities in Shaping the Future of Biomarkers

Biomarkers 2016

Biomarkers 2016

Conference Series LLC Conferences invites all the participants across the globe to attend ‘8th International Conference on Biomarkers and Clinical Research’ during December 05-07, 2016 in Philadelphia, USA which includes prompt Keynote presentations, Oral talks, Poster presentations and Exhibitions.

Biomarkers 2016 will mainly focus on the types of biomarkers,Functional genomics and cytogenetic biomarkers and its clinical research and development, omics technologies  in discovery and its validation, biomarkers of exposure response and susceptibility, biomarkers disorders,techniques to maximize biomarker identification, biomarkers nano science.

Theme: Exploring the Possibilities in Shaping the Future of Biomarkers

Track 1: Biomarkers

Biomarker is a characteristic diagnostic tool that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. Biomarkers can be molecules, or genes, gene products, enzymes, or hormones referred as protein biomarkers, analytical biomarkers, blood biomarkers, fluorescent biomarkers, circulating biomarkers and molecular biomarkers to quantify the degree of disease condition. Biomarkers are the measures used to perform a clinical assessment in case of cancer biomarkers. They predict health states in individuals across populations so that appropriate therapeutic intervention can be planned. In the current scenario more than a thousand organizations and universities have contributed to the field of Biomarkers research especially molecular and cancer biomarkers, with its wings spreading across major organizations in USA, UK, Germany and China. The global biomarkers market is expected to grow from $29.3 billion in 2013 to $53.6 billion in 2018, a compound annual growth rate (CAGR) of 12.8%.Different types of biomarkers include Protein biomarkers, Fluorescent biomarkers, Blood biomarkers, Cancer biomarkers, Analytical biomarkers and Molecular Biomarkers.

Related conferences:

6th World Congress on Cell & Stem Cell Research, February 29-March 02, 2016, USA, 7th Global Summit on Cancer Therapy, October 05-07, 2015, UAE, 5th World Congress on Cancer Therapy, September 28-30, 2015, USA, 9th Indo Global Summit on Cancer Therapy, November 02-04, 2015, India, 8th Euro Global Summit on Cancer Therapy, November 03-05, 2015, Spain, 9th Cancer Therapy conference, November 02-04, 2015, India, Stem Cells & Cancer Conferences February 15-20, 2015 India, 3rd International Oncology Conference September 10 -11th ,2015,UAE, 1st International Nastaran Cancer Symposium, 1ST October2015,Iran, 2nd Annual Oncology Asia 07-08 September, 2015, Japan; 12th Cancer Conferences Europe September 26-28, 2016 London, UK; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer EventsNovember 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

 Track 2Functional Genomics and Cytogenetic Biomarkers

The branch of genomics that determines the biological function and complex association of the genes and their products depicts the functional genomics. The measurable degree of these parameters through various processes and equipment inclusive of Next generation sequencing, Personalized genome sequencing and mi-RNA sequencing utilizing cellular entities to predict SNP biomarkers, immuno fluorescent biomarkers, oxidative stress biomarkers, si-RNA and mi-RNA will aid in better understanding of the disease outcome. The cytogenetic biomarkers are a feasible diagnostic tool to detect DNA and chromatin damage. The newly emerged discipline in the field of cytogenetic and functional genomics is Molecular imaging biomarkers, aids in better visualization of the cellular function and the follow-up of the molecular process in living organisms without penetrance. Roche Diagnostics, GlaxoSmithKline, Siemens Healthcare, GE Healthcare and Merck & Co are a few of the key players in this market as observed in biomarkers congress. The functional genomics and cytogenetic market is estimated to reach 150M$ by 2017.Functional genomics covers various areas of biomarkers applications like Next gen sequencing, Personalized genome sequencing, Micro RNA sequencing and SNP biomarkers. Cytogenetic biomarkers include Immuno flouscent biomarkers, Molecular imaging biomarkers, Oxidative Stress Biomarkers and si-RNA and mi-RNA.

Related conferences

11th Asia Pacific Oncologists Conference, July 11-13, 2016, Kualalumpur, Malaysia, Global Summit on Melanoma and Carcinoma, July 14-15, 2016, Australia, International on Conference on Oral, Mouth and Throat Cancer, August 18-20, 2016, USA, International Conference and Expo on Molecular & Cancer Biomarkers, September 15-17, 2016, Germany, International Conference on Cervical Cancer, September 22-23, 2016, Austria, Conference on Mesothelioma, November 03-04, 2016, Valencia, spain, 7th International Conference on Biomarkers & Clinical Research, November 28-30, 2016, Baltimore, USA, 6th Cancer Therapy Conference, December 01-03, 2016, Baltimore, USA, 4th Conference on Blood Malignancies and Treatment, April 18-20, 2016, Dubai, UAE, World Conference on Lung Cancer,Setember, 2015, USA Circulating Biomarkers  2015 GLASGOW,30-1st September, 2015,USA, WCCBC — World Congress on Controversies in Breast Cancer, October 22-24th, 2015,Australia, Chabner Colloquium: Collaboration in Cancer Drug Trials, October 26 -27, 2015, Boston,  13th Cancer Therapy Conference, October 17-19, 2016, Dubai, UAE; 12th Cancer Conferences Europe September 26-28, 2016 London, UK; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer EventsNovember 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 3Biomarkers in Clinical Research and Development

The Biomarkers finds its valuable application in the field of Clinical research and development by case study and data management as evident through Biomarker conferences. The Bioethics and intellectual property right establishes the norms and standard of conduct of hypothesis with respect to clinical validation of biomarkers. The incorporation of biomarker in clinical trials for various disease conditions will put forth a valid diagnostic and therapeutic approach utilizing even the medical devices to detect clinical biomarkers. Currently this is the booming industry. Most of the reputed organizations like Pfizer, Parexel and Quintiles are into clinical research and development. The companies, hospitals and clinical research organizations are the hot spots for conducting clinical research with its growth rate increasing exponentially by an estimated  75B$ by 2016.In clinical research and development, clinical biomarkers are used in case study and data management, clinical trials and in medical devices.

Related conferences

17th International Conference on Biomarkers and Clinical Research, November 28-30, 2016, USA, 4th International Conference on Blood Malignancies and Treatment, April 18-20, 2016, UAE, 10th Annual Oncologists Meeting, July 11-13, 2016, Germany, Conference on Surgical Oncology, September 01-03, 2016, Brazil, International Conference on Leukaemia and Bone marrow Transplantation, November 10-12, 2016, Turkey, 10th Oncologists Conference, July 11-13, 2016, Cologne, Germany, Conference on Surgical Oncology, September 01-03, 2016, Sao Paulo, Brazil, 12th Cancer Therapy Conference, September 26-28, 2016 , London, UK, Conference on Leukaemia and Bone marrow Transplantation, November 10-12, 2016,  Turkey, Training — Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy, November 10 – 13, 2016, Maryland, CIPO2015 — 4th International Conference on Immunotherapy in Pediatric Oncology, 25-26th September, 2015, PIVAC-15 — The 15th International Conference on Progress in Vaccination Against Cancer, 6-8th October, 2015, Germany, Society for Immunotherapy of Cancer's 30th Anniversary Annual Meeting & Associated Programs, ABC3 — Advanced Breast Cancer Third International Consensus Conference (ABC3),5-7th November,2015 , Cancer Vaccines: Targeting Cancer Genes for Immunotherapy,. March 6—10, 2016, Canada; 12th Cancer Conferences Europe September 26-28, 2016 London, UK; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer EventsNovember 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 4: Omics Technologies in Biomarkers Discovery and Validation

Biomarkers play a critical role in disease diagnosis and treatment, especially for the early detection of cancer, to enable screening of asymptomatic populations. Recent omics technologies, such as Transcriptomics, genomics and proteomics approaches besides Metabolomics are accelerating the rate of biomarker discovery. The incorporation of techniques like microarray data analysis, computational biology, data mining methods, Transcriptomics and profiling techniques are playing a crucial role in the validation of biomarkers. Since the Human Genome Project was completed in April 2003, genome-wide association studies (GWAS) have contributed toward a greater understanding of the genetic basis of complex diseases and advances in high-throughput technologies. This has enabled researchers to rapidly map the genome of vertebrates, invertebrates and pathogens through cost-effective methods. The applications of Bioinformatics tool in biomarker research is the current emerging field promoting better diagnosable parameters. The global omics market was valued at nearly $2.8 billion in 2011, nearly $3.2 billion in 2012, and is forecast to grow to nearly $7.5 billion by 2017 after increasing at a compound annual growth rate (CAGR) of 18.7%. The omics technology segment holds the largest share of ~75% of the biomarker discovery market, primarily due to the increase in adoption of proteomics and genomics technologies, globally. There are several approaches in biomarkers discovery and validation like genomics and proteomic approaches, Microarray data analysis, Data mining methods and Transcriptomics and profiling techniques by making use of Computational biology and Application of Bioinformatics in biomarker discovery.

 Related conferences

2nd International Conference on Prostate Cancer and Treatment, August 22-23, 2016, USA, Experts Meeting on Gynaecologic Oncology, May 19-21, 2016 , USA Cancer Diagnostics Conference and Expo, June 13-15, 2016, Italy, 11th Asia Pacific Oncologists Conference, July 11-13, 2016, Kualalumpur, Malaysia, Global Summit on Melanoma and Carcinoma, July 14-15, 2016, Australia, Controversies in Breast Cancer  (CoBRA) October 22-24, 2015, Australia, 16th Biennial Meeting of the International Gynaecologic Cancer Society, 29-31stOctober 2016, Lisbon, WSMOS Fall Oncology Conference, 30th October 2015,Uk,  Next NRG Oncology  Semiannual Meeting, Jan 21-24th ,2015, Atlanta, Progress and Controversies in Gynaecologic Oncology Conference, 16-17 January 2015, Spain; 12th Cancer Conferences Europe September 26-28, 2016 London, UK; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer EventsNovember 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 5: Biomarkers of Exposure Response and Susceptibility

Biomarkers of exposure are important in toxicology, because they are an indicator of internal exposure and genetic susceptibility to drug, chemicals or the amount of chemical exposure that got accumulated in the body. Significant advances have been made in developing analytical methods that detect and quantify many natural or synthetic toxins or their breakdown products in the biological matrix. The ability to accurately measure biomarkers of exposure depends upon an adequate understanding of the chemistry and toxicology of the substance under consideration. Epigenetic biomarkers also quantify the degree of exposure to toxic dynamic and pharmacodynamics parameters in pathological and biochemical changes occurring due to exposure to harmful agents, brought to light by toxic dynamics meetings and pharmacodynamics workshops. This emerging field of study is gaining importance in industry with an estimate of more than 7,287 personnel conducting study across the globe. While studying the response and susceptibility parameters like toxic dynamic and pharmacodynamic parameters are taken into consideration to measure the internal exposure and genetic susceptibility to drugs and chemicals.

Related conferences

7th International Conference on Biomarkers and Clinical Research, November 28-30, 2016, USA, 4th International Conference on Blood Malignancies and Treatment, April 18-20, 2016, UAE, 10th Annual Oncologists Meeting, July 11-13, 2016, Germany, Conference on Surgical Oncology, September 01-03, 2016, Brazil, International Conference on Leukaemia and Bone marrow Transplantation, November 10-12, 2016, Turkey, 15th World Conference on Lung Cancer, October 27-31st 2015, Autralia, 14th International Lung Cancer Congress, July 25-27, USA, Chimeric Antigen Receptor Therapy in Haematology and Oncology: Current Successes and Challenges, 19—20 October 2015, UK, South Africa Meeting on Translational Cancer Research , 12-16 October 2015,South Africa, Cancer Diagnostics Conference,03 - 04 September 2015,UK; 12th Cancer Conferences Europe September 26-28, 2016 London, UK; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer EventsNovember 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 6Biomarkers for Disorders

Biomarkers are the characteristic biological measurable indictors for the various disorders if occurring in abnormal levels. These are used as quantitative entities for neurological disorders, genetic disorders, metabolic disorders, cardiac disorders and inborn errors. The present era is focusing on the cancer research utilizing biomarkers as indictor of disease conditions. The lung cancer biomarkers and biomarkers for breast cancer are inclusive of genes, enzymes, proteins and cell surface entitles. Registering a compound annual growth rate of 14.60% from 2011 to 2018, the market for oncology biomarkers was valued at $13.16 billion in 2011 and is expected to be worth $29.78 billion in 2018.Biomarkers are also used in diagnosing and treating various diseases and disorders like Neurological disorders, Genetic disorders, Metabolic disorders, Cardiac disorders, Inborn errors, Lung cancer and Breast cancer.

Related conferences

International on Conference on Oral, Mouth and Throat Cancer, August 18-20, 2016, USA, International Conference and Expo on Molecular & Cancer Biomarkers, September 15-17, 2016, Germany, International Conference on Cervical Cancer, September 22-23, 2016, Austria, International Conference on Mesothelioma, November 03-04, 2016, Spain, 7th International Conference on Biomarkers and Clinical Research, November 28-30, 2016, USA, Conference on Clinical Cancer Research Synergy 2016: A Multidisciplinary Approach to Interventional Oncology, Exosomes and Micro vesicles as Biomarkers and Diagnostics Meeting Cambridge UK, Cancer Metabolism Conference —Cancer Metabolism Conference Washington USA, conference, June 7 - 10, 2015, USA , Cancer and Autoimmunity 2016 — Emerging Target Therapies in Cancer & Autoimmunity, 21-25 April, 2016, Cuba, Markers in Cancer Diagnostic Development Tutorial, December 1-2, 2015, Germany, VI Inter American Oncology Conference: 'Current Status and Future of Anti-Cancer Targeted Therapies' 2016, South America; 12th Cancer Conferences Europe September 26-28, 2016 London, UK; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer EventsNovember 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 7Techniques to Maximize Biomarker Identification

Biomarkers are the existing bimolecular and integral indictors of disease condition of biological systems. The techniques used to identify and maximize the expression of biomarkers include RT-PCR genotyping, molecular imaging and dynamics, biochemical  assay and profiling, immunological techniques and chromatographic techniques. A wider approach towards identification of biomarkers lies in the proteomic approach besides utilizing biosensors as a compatible tool for evaluation of biomarker levels in the biological systems. Most of the company’s focus on generating cost effective durable profiling techniques and equipment to quantify biomarkers within a short span of time. Johnson & Johnson, GlaxoSmithKline Plc., GE Healthcare, Affymetrix Inc., Bio-Rad Laboratories Inc. are a few of the key players in this market. Partnerships, agreements, collaborations, & mergers and acquisitions are the key business strategies adopted by market participants to ensure their growth in the market.

Related conferences

Cancer Diagnostics Conference and Expo, June 13-15, 2016, Italy, 11th Asia Pacific Oncologists Conference, July 11-13, 2016, Kualalumpur, Malaysia, Global Summit on Melanoma and Carcinoma, July 14-15, 2016, Australia, Conference on Surgical Oncology, September 01-03, 2016, Brazil, International Conference on Leukaemia and Bone marrow Transplantation, November 10-12, 2016, Turkey, International Society of Paediatric Oncology, 8-11th October, South Africa, 3rd International Conference on UV and Skin Cancer, 2015, USA ,Australia, Inaugural International Adolescent and Young Adult Oncology Congress Sydney Australia., 17th International Conference on Lung Cancer: Venice Italy, The 2nd Royal Marsden Thyroid Cancer Conference, 15 June 2015, UK; 12th Cancer Conferences Europe September 26-28, 2016 London, UK; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer EventsNovember 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 8Biomarkers in Nano science

Nano science is the study of structures and materials on the scale of nanometres. Nanotechnology may be able to create many new materials and devices with a vast range of applications in medicine, electronics, biomaterials energy production, and consumer products. Nanotechnology is evolving rapidly with nanoparticles events.  An estimated 1 million workers in R&D and production are involved in the field of Nano science and nanomaterial generation. Interaction of biomarkers with nanoparticles aids in identification and validation through biological and biomedical applications. Current market holds Nano devices and nanomaterial for identification, quantifying, calibrating and even in surgeries. The US leads the world in investing and in the number of Nanotech Companies. Global consumption of nanomaterial is expected to grow in unit terms from nearly 225,060 metric tons in 2014 to nearly 584,984 metric tons in 2019, a compound annual growth rate (CAGR) of 21.1% for the period of 2014 to 2019.Nano science is another rapidly growing area where application of nanotechnology to biomarkers is used for biological and biomedical applications like Nano devices.

Related conferences:

Global Summit on Melanoma and Carcinoma, July 14-15, 2016, Australia, International on Conference on Oral, Mouth and Throat Cancer, August 18-20, 2016, USA, International Conference and Expo on Molecular & Cancer Biomarkers, September 15-17, 2016, Germany, International Conference on Cervical Cancer, September 22-23, 2016, Austria, International Conference on Mesothelioma, November 03-04, 2016, Spain, 17th International Conference on Lung Cancer: Italy, 3rd International Conference on UV and Skin Cancer  Australia, Inaugural International Adolescent and Young Adult Oncology Congress Sydney Australia. Economics of  Cancer Research Group, July 22, 2015,USA; 12th Cancer Conferences Europe September 26-28, 2016 London, UK; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer EventsNovember 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

 

OMICS International Conferences cordially invites all the participants across the globe to attend the “8th International Conference on Biomarkers & Clinical Research” during December 05-07 at Philadelphia, USA.

Biomarker congress will enable to put forth the holistic scientific approach to validate the existing and development of novel biomarkers as to better understanding of diseases and diagnosis. The past five conference series of biomarkers meeting have grounded the best possible researchers in the field of biomarkers from diverse scientific disciplines, and so will be the upcoming.

Biomarkers are important for streamlining drug discovery and development. In addition, biomarkers can be widely used as a tool for disease diagnosis, personalized medication in clinical research. Study design and statistical analysis for biomarker research incorporates various tools from bioinformatics. It further involves patient segmentation and stratification by successful integration of diagnostic tools and clinical data annotation inclusive of classification distribution metrics and pattern recognition. The global market for biomarkers in data statistics is estimated at about $2.4 billion in 2011 and further projected to reach $7.6 billion by 2017 registering a CAGR of 18.3% during the period 2007-2017. The organizations involved are Affymetrix, Agilent Technologies, Biomax Informatics, Illumina, Qiagen etc amongst others across the globe.

OMICS International is a pioneer and leading scientific event organizer, publishing around 700+ Open access journals and conducting over 500 Scientific Meetings all over the globe annually with the support of more than 1000 scientific associations, 80,000 editorial board members, and 7.5 million followers to its credit.

Why to attend???

With members from around the world focused on learning about Biomarkers and Clinical Research; this is your best opportunity to reach the largest assemblage of participants from the Biomarkers and Clinical Research community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with advanced treatments, and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Biomarkers and Clinical Research are the hallmarks of this conference.

Target Audience:

Biomarkers and Clinical Research Scientists, Students

Biomarkers and Clinical Researchers

Biomarkers and Clinical Research Faculty

Biomarkers and Clinical Research Associations and Societies

Medical Colleges

Psychiatrists

Business Entrepreneurs

Training Institutes

Software developing companies

Manufacturing Medical Devices Companies

Data Management Companies

 

 

Theme: Lab to Industry as Bio signatures to Therapeutic Discovery

Summary (Overall Market of Biomarkers & Clinical Research with Statistics):

The global biomarkers market is expected to reach $45.55 Billion by 2020 from $24.10 Billion in 2015, at a CAGR of 13.58% between 2015 and 2020. Increasing healthcare expenditure & R&D spending and the increasing utility of biomarkers for diagnostics are expected to drive the market. Market growth will also be aided by the low cost of clinical trials in developing countries and new initiatives undertaken for biomarker research. On the other hand, the need for high capital investment, low benefit-cost ratio, poorly suited regulatory & reimbursement systems, and the high cost of tests and sample collection & storage are the major factors restraining the growth of this market.

The applications included in this report are diagnostics development, drug discovery & development, personalized medicine, disease risk assessment and other applications. The disease indication segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.

Major players in this market include QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), Bio-Rad Laboratories (U.S.), Enzo Biochem (U.S.), EKF Diagnostics Holdings plc (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France), and Signosis, Inc. (U.S.).

Global Biomarkers Market, by Type

  • Safety Biomarkers
  • Efficacy Biomarkers
    • Pharmacodynamics Biomarkers
    • Predictive Biomarkers
    • Prognostic Biomarkers
    • Surrogate Biomarkers
  • Validation Biomarkers

Global Biomarkers Market, by Application

  • Diagnostics Development
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Other Applications

Global Biomarkers Market, by Disease Indications

  • Cancer
  • Cardiovascular Disorders
  • Neurological Disorders
  • Immunological Disorders
  • Other Diseases

Global Biomarkers Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
  • Asia
  • Rest of the World

The geographic analysis reveals that North America will account for the largest share of the global biomarkers market in 2015. Growth in this market can be attributed to strong growth trends in pharmaceutical companies and CROs. The Asian regional segment is expected to register double-digit growth from 2015 to 2020 owing to the expansion of leading biomarker companies and increased R&D spending. R&D spending in Asia increased from $177 billion in 2003 to $329 billion in 2010, at a CAGR of 9.29%. The R&D spending in Asia accounted for 27.13% of the global R&D expenditure in 2010.

The Omics technology segment holds the largest share of ~75% of the biomarker discovery market, primarily due to the increase in adoption of proteomics and genomics technologies, globally.

The emerging Asia-Pacific region exhibits high growth opportunities for industry participants. Growing economies such as China and India are experiencing an increasing rate of biomarkers research activities. This is attributed to the rising number of contract research organizations and the low cost of conducting clinical trials in Asia-Pacific nations when compared to developed countries.

Importance & Scope:

For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute to capture profit from opportunity.

The biomarkers market presents the largest of all opportunities in representative disease subsegments. This study investigates one of the most important market drivers: the introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil and Russia.

This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.

Scope of Report

Current and projected product forecasts during the forecast period (2013 to 2018) are discussed. In addition, new products approved in 2012 and 2013 by the FDA, and those products expected to be approved within the forecast period, are projected. Figures are estimated for 2013, except where actual results have been reported, due to the timing of the release of the report. For all areas, including very large markets segments such as infectious disease and cardiovascular, specific mechanisms of action are discussed in detail. Market figures include the bundled value of the drug and the biomarker as it is impossible to quantitate the composite values of each.

The report includes an analysis of leading and emerging competitors in the current worldwide biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies.

Why Baltimore, USA?

In a study conducted to evaluate a change in symptoms and radiographic features in patient with the help of Biomarkers, they identified that the research related to biomarkers was oftenly conducted in Baltimore, USA.  There are more than 200 research firms in Baltimore.

There are several self-sustaining, not-for-profit, research support organization focused on facilitating the identification, quantification and validation of biomarkers for use in diagnosis, prognosis and treatment of diseases in Baltimore.

Conference Highlights:

  • Types of Biomarkers
  • Functional Genomics and Cytogenetic Biomarkers
  • Functional Transcriptomics and Profiling Techniques
  • Biomarkers in Clinical Research and Development
  • Omics Technologies in Biomarkers Discovery and Validation
  • Biomarkers of Exposure Response and Susceptibility
  • Biomarkers for Disorders
  • Techniques to Maximize Biomarker Identification
  • Biomarkers and Nano particles

Why to attend Biomarkers?

Team Biomarkers aims to deliver a perfect platform to the scientific and industry personnel to share their knowledge and expertise. It gives opportunity to conduct demonstrations, distribute information, meet with current and potential speakers/Delegates all around the world which are working on the very emerging field of Biomarkers, and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Biomarkers and Clinical Research fields are hallmarks of this conference.

A Unique Opportunity for Advertisers and Sponsors at this International event: http://biomarkers.conferenceseries.com/sponsors.php

Major associations and media partners around the globe:

  • Biomarkers Profile corporation
  • International society for oncology and Biomarkers
  • The Biomarkers consortium
  • World molecular imaging society
  • Society of nuclear medicine and molecular imaging
  • European society of molecular imaging
  • Biomarkers Society
  • Genetic engineering and Biotech News
  • Insight Pharma
  • Bio IT World

Major associations and media partners around USA:

  • Alliance for commercialization of Canadian Technologies
  • University Health Networks
  • Ontario Cancer Biomarker Network
  • National Research council
  • Canadian association of Neuroscience
  • Clinical Research association of Canada
  • Hypertension Canada
  • Biotechnology Canada

Target Audience:

For Biomarkers mainly the target audiences are Universities, Research institutes, Hospitals, Industries, Medical device manufacturing companies, CROs and Associations.

Top Universities in USA:

  • The Johns Hopkins University
  • Massachusetts Institute of Technology
  • University of Maryland
  • University of Pennsylvania
  • University of Illinois
  • Harvard University
  • Duke University

Glance at market of Biomarkers and Clinical Research:

Total market value of Biomarkers in 2014 is $5.95 Billion and it is expected to reach $30 Billion in 2020 growing at CAGR of 16% from 2014 to 2020. Biomarkers major verticals are usually supplied by market of application and market of services. Common Annual Growth Rate of more than 37% is gained by market for application and Common Annual Growth Rate of more than 39% are gained from the market of services. Thus the common annual growth is 49% by revenue. Nowadays scope of biomarkers has a vital role in efficacy of the therapeutic process all around the world. Establishing the standardization of drug development has a major role for the development of disease pathway. Also, Research portfolio of biomarkers discovery has an application in all the major scientific studies.

Biomarkers-2015

OMICS International hosted the “6th International Conference on Biomarkers & Clinical Research” (Biomarkers 2015) during August 31–September 02 at Toronto Airport Marriott Hotel, Toronto, Canada. The scientific meeting has laid path for the designing and development of research methodologies with the theme impact of “Lab to industry as bio-signatures to therapeutic discovery”.

Biomarkers 2015 was fortunate to acquire support from association and societies - Clinical Research Association of Canada (CRAC), Hypertension Canada, International Society for Cellular Therapy (ISCT), The Egyptian Biophysical Society and media partners -Biomarkers Profile Corporation, Gate2Biotech, The Technology Networks, Council of European Bio-Region, Oncology Education and Edinburgh Science Triangle.

The highlights of the meeting were the eponymous lectures, delivered by Dr. Claude Prigent, University of Rennes, France, Dr. Trevor G Marshall, Autoimmunity Research Foundation, USA,  Dr. Alain Moreau, Sainte-Justine University Hospital, Canada, Dr. Sergey Suchkov, I. M. Sechenov First Moscow State Medical University, Russia, Dr. Alexander M Buko, Human Metabolome Technologies, USA, Dr. Chee Gee See, Proteome Sciences, UK, Dr. Biswendu B Goswami, FDA Center for Food Safety and Applied Nutrition, USA.

Biomarkers 2015 held pre-conference workshop on August 1, 2015 in Mumbai University, India under the supervision of Prof. K. P. Mishra, Founder President of Society of Radiation Research, India. The workshop gathered 650+ participants inclusive of students, faculty, societies and industrial personnel.

The conference held 2 workshops under the supervision of Prof. Sergey Suchkov, I. M. Sechenov First Moscow State Medical University, Russia; Dr. Trevor G Marshall, Autoimmunity Research Foundation, USA and their team from Czech Republic and Prof. Youhe Gao, Beijing Normal University, China.


Past Reports  Proceedings  Gallery  

Biomarkers-2014

The 5th International Conference on Biomarkers & Clinical Research, the Biomarker-2014, was held during April 15-17, 2014 at Oxford, UK.

Biomarkers-2014 has taken up the scientific thoughts towards proving the importance of accurate diagnostics to be prevital towards the curing efficacy. The scientific meeting has laid path for the designing and development of research methodologies with the theme impact of “Diagnostic significance of the therapeutic bio-clinical molecule”.

The conference was greeted by the welcome message from President’s desk at the European Association for Predictive, Preventive and Personalised Medicine (EPMA), Brussels, EU. The support was extended through the PPPM workshop being conducted with the PPPM representatives from Russia, USA, Czech Republic and Saudi Arabia. The conference has gathered support from Everest Biotech, EuroScienceCon, Biomarkers Profile Corporation, ArrayMold, BioNews, Edinburgh Science Triangle, Biowebspin, The Technology Networks, European Biotechnology Thematic Network Association, Visiongain and Current Partnering as the media partners. In addition SCIENION has participated at the conference as Exhibitor at this conference.

The program highlights of the meeting were the eponymous lectures, delivered by Dr. Sergey Suchkov from I.M.Sechenov First Moscow State Medical University, Russia; Dr. Pavel Vodicka from Institute of Experimental Medicine, Czech Republic; Dr. Ondrej Topolcan from Charles University in Prague, Czech Republic; Dr. Claudio Nicolini from University of Genova, Italy and Dr. Claude Prigent from University of Rennes, France.


Past Reports  Gallery  

Biomarkers-2013

OMICS Group organized 4th International Conference on Biomarkers & Clinical Research, during July 15-17, 2013 at Philadelphia, USA under the theme of “Impact of Biomarkers Development in Health Diagnostics and Clinical Research”.

The conference was initiated with a series of invited lectures delivered by Dr. Jizu Yi from BD Diagnostics, USA; Dr. Yaping Tian from PLA General Hospital, China; Dr. Leticia Cano from Biomarker Profile Corporation, USA and Dr. Lawrence Greenfield from Affymetrix, USA.


Past Reports  Gallery  

Biomarkers-2012

The 3rd International Conference on Biomarkers & Clinical Research, organized by theOMICS Group was held on July 2-4, 2012 at Embassy Suites Las Vegas, USA under the theme of "Commercialization of Biomarkers". There were about 200 delegates representing 25 countries from different corners of the world who made this conference a big success in the field of Biomarkers and Clinical Research.

The conference was initiated with a series of invited lectures delivered by both Honorable Guests and members of the Keynote forum. The list includes Dr. Josip Blonder, Frederick National Laboratory for Cancer Research (NIH), USA; Dr. Marcel M. Daadi, Stanford University, USA; Dr. Ting-Chao Chou, Memorial Sloan-Kettering Cancer Center, USA; Dr. Jacob Kagan, National Cancer Institute, NIH, USA; Dr. Michael Sullivan, Worldwide Clinical Trials-Drug Development Solutions, USA; Dr. Hitoshi Sohma, Sapporo Medical University Center for Medical Education, Japan and Dr. Da Zhi Liu, University of California at Devis, USA. All the above mentioned Honourable Guests and Keynote speakers gave their energetic and fruitful contributions at Biomarkers-2012. All accepted abstracts have been indexed in OMICS Group Journal of Molecular Biomarkers & Diagnosis as a special issue. 


Past Reports  Gallery  

Biomarkers-2011

OMICS Group organized 2nd World Congress on Biomarkers & Clinical Research in the most populous city of United States, the seat of Clark Country, on September 12-14, 2011. This annual conclave comprised of 10 Tracks and 44 sessions with a grand inaugural ceremony followed by a Keynote forum. The motive of this International conference was to emphasize on "Strategies and Developments in Biomarkers & Clinical Research."

This meeting brought together eminent scientists, scholars and entrepreneurs from across 30 countries in which many critical issues were discussed in depth to provide up-to-date information to the world. We take great pleasure to express our deep felt thanks to all the following keynote speakers:
Dr. Abdel Halim, Director, Daiichi-Sankyo Pharma Development, USA
Dr. Crispin R. Dass, Victoria University, Australia 
Dr. Jean Gabert, Université de la Méditerranée, France
Mr. Jeremy Warren, NanoSight Ltd, UK

OMICS Group will acknowledge with gratitude the support by FDA, Nanosight Ltd, AstraZeneca R&D, Biologics Consulting Group, Inc. Daiichi-Sankyo Pharma Development, etc. 


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date December 05-07, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2 Day 3
Poster Opportunity Available

Conferenceseries Destinations